ライフサイエンスコーパス: anti-HIV agent

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 icacy of PNA(TAR)-transportan as a potential anti-HIV agent.

2 novel and selective antiviral, in particular anti-HIV agents.

3 cilitate the development of a novel class of anti-HIV agents.

4 from the library failed to yield any active anti-HIV agents.

5 novel N-DABOs were synthesized and tested as anti-HIV agents.

6 will lead to the discovery of a new class of anti-HIV agents.

7 tic basis for the discovery of new selective anti-HIV agents.

8 L-2'F-C-d4Ns) were synthesized as potential anti-HIV agents.

9 ies, which may aid in the development of new anti-HIV agents.

10 described identify new potential targets for anti-HIV agents.

11 resistant to all of the currently available anti-HIV agents.

12 heir consideration as therapeutically useful anti-HIV agents.

13 he development of biopharmaceutically useful anti-HIV agents.

14 tating identification of the next generation anti-HIV agents.

15 interactions warrant the development of new anti-HIV agents.

16 The anti-human immunodeficiency virus (anti-HIV) agent 2',3'-didehydro-3'-deoxythymidine (D4T),

17 of (+)-cis-khellactone derivatives as novel anti-HIV agents, 24 monosubstituted 3', 4'-di-O-(S)-camp

18 rugs in the brain is expected to produce the anti-HIV agent, 9-(2,3-dideoxy-2-fluoro-beta-D-threo-pen

19 amidates 2a, 2b, 4a, 4b, and 6 derived from anti-HIV agent adenallene 1a, 3a, inactive hypoxallene 1

20 Both a potent anti-HIV agent and an efficient formulation are required

21 ty relationships (SAR) of triterpene-derived anti-HIV agents and led to the design and synthesis of c

22 carboxypeptidase lability translated to poor anti-HIV agents and vice versa, so the assay became pred

23 -tetraazamacrocycle xylyl-bicyclam, a potent anti-HIV agent, by the coreceptor CXCR4, a G-protein-cou

24 The anti-HIV agent (+/-)-calanolide A (1) has been synthesiz

25 at Gd-Tex may have therapeutic utility as an anti-HIV agent capable of selectively targeting and remo

26 The anti-HIV agent cosalane inhibits both the binding of gp1

27 ine the role of the cholestane moiety in the anti-HIV agent cosalane, a series of cosalane analogs wa

28 on of our previous works in the discovery of anti-HIV agents, D- and L-2',3'-unsaturated 3'-fluoro ca

29 ng study of triterpene derivatives as potent anti-HIV agents, different C-3 conformationally restrict

30 on towards enantioselective synthesis of the anti-HIV agent (-)-equisetin.

31 f great interest which is not reached by any anti-HIV agent in clinical use.

32 nscriptase inhibitors (NNRTIs) are effective anti-HIV agents in cell culture.

33 ology to the total synthesis of siamenol, an anti-HIV agent, is reported.

34 was found to possess enhanced potency as an anti-HIV agent relative to cosalane itself.

35 ucture-activity relationship study of potent anti-HIV agents, seven new triterpene derivatives were d

36 In a continuing study of potent anti-HIV agents, seventeen 28,30-disubstituted betulinic

37 de designed as a conformational mimic of the anti-HIV agent stavudine (1, D4T) is described.

38 nal ring (IVR) for sustained delivery of the anti-HIV agent tenofovir (TFV) are described.

39 Bevirimat (1, BVM) is an anti-HIV agent that blocks HIV-1 replication by interfer

40 are safe, and thus, if developed for use as anti-HIV agents, they could reduce both HIV replication

41 nd 29, which were confirmed as highly potent anti-HIV agents with activities in the 10-20 nM range.

42 llene 1a and (R)-enantiomer 3a are effective anti-HIV agents with EC50 approximately 0.88 and 0.21 mi

43 ying of several polychloro-analogs did yield anti-HIV agents with EC50 values as low as 310 nM.

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。